ADC usage in breast cancer treatment increased 3.7-fold from 2021 to 2023, with significant reductions in median time to treatment. Older women experience lower ADC treatment rates and longer delays ...
ADCs have transformed bladder cancer treatment, but challenges like toxicity management and high costs remain significant hurdles. ADCs vary in components and mechanisms, influencing outcomes and ...
The antibody-drug conjugate (ADC) manufacturing landscape offers the potential to leverage significant opportunities for cancer treatment, but faces complex challenges. Nevertheless, the ADC market ...
Regeneron is pretty good at making antibodies. It’s kind of its thing. But, while the industry has gone deal crazy for antibody-drug conjugates (ADCs), the company has stayed out of the limelight.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results